Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the US
Details : Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Product Name : Cetrotide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apotex Launches Generic Dasatinib Tablets in The U.S.
Details : Sprycel (dasatinib) is an oral film-coated tablet, a protein kinase inhibiting small molecule drug. It is indicated for the treatment of chronic myeloid leukemia.
Product Name : Sprycel-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2024
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Ambio
Deal Size : Inapplicable
Deal Type : Inapplicable
Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States
Details : Teriparatide Injection, a single-patient-use pre-filled pen and a parathyroid hormone analog, is used for the treatment of osteoporosis in the United States.
Product Name : Teriparatide-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Ambio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Advisory - Apotex Recalls Apo-Acyclovir Tablets Due to a Nitrosamine Impurity
Details : Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.
Product Name : Apo-Acyclovir
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brimonidine Tartrate,Timolol Maleate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company launched Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution which is a generic version of Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2022
Lead Product(s) : Brimonidine Tartrate,Timolol Maleate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable